Health Literacy in Medicines Use and Pharmacy: A Definitive Guide highlights issues related to medication literacy from the context of the pharmacist and other healthcare professionals. This definitive guide will undoubtedly serve as an invaluable resource for healthcare professionals in training and practice, fostering excellence in patient care globally. The book provides a clear explanation of medication literacy, presents different tools to assess health and medication literacy, readability, and comprehensibility of written medicine information (WMI), and elaborates on different approaches to develop customized and patient-friendly WMI. The book also covers health and medication literacy in special populations, including geriatrics, pediatrics, and pregnant/lactating patients. Written by experts in health communication, this book will help pharmacists, other health professionals, educators, students, and regulators, who need to develop customized educational materials that can be understood by a broad range of patients, especially those with low health literacy.

�ber die Autorinnen und Autoren

Prof. Ahmed Awaisu is a Professor of Clinical Pharmacy & Practice. He is currently the Head of the Department of Clinical Pharmacy and Practice in the College of Pharmacy at Qatar University. His research interest includes outcome-based research, pharmacoepidemiology and medication safety, pharmacy education, and health promotion. Prof. Awaisu has established a medication use optimization research niche using generous funds from Qatar University, Qatar National Research Fund, Hamad Medical Corporation, and other agencies. He has been involved in mentoring PhD, MSc, and undergraduate research projects related to prescribing/deprescribing, medication adherence, medication safety, quality of life, and other health-related outcomes.

Prof. Ahmed Awaisu was the former Associate Editor of Value in Health Regional Issue (CEWAA). He was also the Section Editor (Clinical Pharmacy) for the Elsevier-published textbook entitled “Encyclopedia of Pharmacy Practice and Clinical Pharmacy�. He was also the former Chair of the Qatar University Institutional Review Board.

Prof. Awaisu was the recipient of the “Qatar University Merit Award for Outstanding Faculty� in September 2017 and the “Qatar University Research Excellence Award in Medical, Biomedical and Health Sciences� in April 2019. He was also the recipient of the “Best New Investigator Award� by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) during the 14th Annual ISPOR European Conference in Madrid, Spain in November 2011. He has served as the WHO Lead Consultant for reviewing the health system development in some countries. He is a member of the American College of Clinical Pharmacy (ACCP), and the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), among others.

The scholar is a very passionate and outstanding scholar whose vision is to make sustainable impact in the society through grooming competent healthcare professionals, mentoring novice researchers, high-impact innovative research, and advancing healthcare.

Dr. Emad Eldin Munsour holds a PhD degree in Pharmacy Practice from Universiti Sains Malaysia and has around 21 years in Pharma-regulatory and compliance area. He looks after the authorization of pharmaceutical products, including evaluation of bioequivalence studies, clinical trials, and Pharmacovigilance system, in addition to CMC (Chemistry, Manufacturing, and Controls). Dr. Emad is the editor of Qatar National Formulary (QNF) and is a professional reviewer for the WHO bulletin and Value in Health Regional issues. He is also involved in many projects related to Qatar National Health Strategy (NHS), including, the National Drug Coding, Generic use and advancement of the pharmaceutical legislative framework. He participated in the activities of National Pharmacovigilance Center (Associate Member of Uppsala Monitoring Center, WHO).

Dr. Emad is currently leading the national pharmaceutical track and trace project in Qatar and actively engaged in GS1 implementation in the healthcare sector; he is also engaged in the development and implementation of national medicines security strategy. Emad is a member of the working group for the establishment of policies and mandates for regulating national pharmaceuticals related Digital Health/e-Health data and interoperability standards.

His research interest in the area of health and medication literacy, drug and poisons information services quality of life and patient reported outcome; he shared his research in various international conferences and published several articles on pharmaceutical care and other pharmacy practice areas.

Parisa Aslani, BPharm(Hons), MSc, GradCertEdStud (Higher Ed), PhD, MRPharmS, FPS, FFIP, FANZCAP, is a Professor in Medicines Use Optimisation at The University of Sydney, Australia. She is known internationally for her research in the areas of consumer medicines information and adherence to therapy. Her research has impacted policy and education in the healthcare sector, and at the Australian Government level, and has led to a global initiative on developing medicine information strategies for implementation at national and local levels. Her research skills range from qualitative techniques to survey design and randomized control trials.

Dr. Rabia Hussain is a Senior Lecturer at the School of Pharmaceutical Sciences, Universiti Sains Malaysia, located in Penang. She is a renowned researcher in the field of medicine safety, pharmacovigilance, medication adherence, and clinical pharmacy. Her research has been published in high-impact journals and focuses on pharmacovigilance, research methods in pharmacy practice, clinical pharmacy, and issues related to medicines use.

Dr. Hussain has collaborated with ReAct - Action on Antibiotic Resistance and Health Action International, Asia Pacific, to improve the use of antibiotics. She is the Section Editor for the Journal of Pharmaceutical Policy and Practice (JoPPP) and has edited "Encyclopaedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy (Elsevier)". Dr. Hussain is a fellow of the Royal Society for Public Health, and she has been nominated as the Apex Young Scholar by Universiti Sains Malaysia.

With over 25 years of experience in pharmaceutical policy and practice research, Prof Zaheer Babar is a global authority and a prolific author in this field. He comes with a long-standing academic career in pharmacy in New Zealand, and the United Kingdom. He is globally known for his work in policy and practice, including quality use of medicines, and issues related to medicines access and pricing.

Prof. Babar has published over 300 papers and is considered the leading researcher in the “pharmacy practice research category�. He has published in high-impact journals such as PLoS Medicine and the Lancet and has acted as a consultant for the WHO, RPS, UNDP, HAI, MSH, FIP, International Union Against Tuberculosis and Lung Disease, World Bank, European Union, and the Pharmaceutical Management Agency of New Zealand. His edited work includes "Economic Evaluation of Pharmacy Services", "Pharmaceutical Prices in the 21st Century", "Pharmaceutical Policies in Countries with Developing Healthcare Systems", "Global Pharmaceutical Policy", "Access to high-cost medicines", "Pharmacy Practice Research Methods", "Pharmacy Practice Research Case Studies" , "Encyclopaedia of Pharmacy Practice and Clinical Pharmacy", and "Encyclopaedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy". Published by Elsevier and Adis/Springer, his work is used in curriculum design, policy development, and referral all around the globe. Professor Babar is the founding Editor-In-Chief of the Journal of Pharmaceutical Policy and Practice [IF = 4.2], a high-impact publication that provides evidence-based insights and recommendations for policymakers, practitioners, and researchers. He can be contacted at: z.babar@hud.ac.uk

��ber diesen Titel� kann sich auf eine andere Ausgabe dieses Titels beziehen.

Anbieterinformationen

Zur Homepage des Verk�ufers

Unternehmensdaten des Verk�ufers

Edward Bowditch Ltd
Exstowe, Exton, Exeter, EX3 0PP, United Kingdom

Gesch�ftsbedingungen und Versandinformationen

Verkaufsbedingungen

Legal entity name: Edward Bowditch Ltd
Legal entity form: Limited company
Business correspondence address: Exstowe, Exton, Exeter, EX3 0PP
Company registration number: 04916632
VAT registration: GB834241546
Authorised representative: Mr. E. Bowditch

Widerrufsrecht

Wenn Sie Verbraucher sind, k�nnen Sie gem�� den folgenden Bestimmungen vom Vertrag zur�cktreten. Verbraucher ist jede nat�rliche Person, die zu Zwecken handelt, die nicht ihrer kaufm�nnischen, gewerblichen, k�nstlerischen oder beruflichen T�tigkeit zugerechnet werden k�nnen.

Informationen zum Widerrufsrecht

Gesetzliches Widerrufsrecht

Sie haben das Recht, den Vertrag innerhalb von 14 Tagen ohne Angabe von Gr�nden zu widerrufen.

Die Widerrufsfrist betr�gt 14 Tage ab dem Tag, an dem Sie oder ein von Ihnen benannter Dritter, der nicht der Transporteur ist, die letzte Ware oder den letzten Posten oder das letzte Exemplar in Besitz genommen hat.

Um das Widerrufsrecht auszu�ben, f�llen Sie auf unserer Website unter „Meine Eink�ufe" in „Mein Nutzerkonto" eine eindeutige Erkl�rung elektronisch aus und senden Sie sie ab. Wir werden Ihnen unverz�glich eine Best�tigung �ber den Eingang eines solchen Widerrufs auf einem dauerhaften Datentr�ger (z. B. per E-Mail) �bermitteln.

Um die Widerrufsfrist einzuhalten, reicht es aus, dass Sie Ihre Mitteilung �ber die Aus�bung des Widerrufsrechts vor Ablauf der Widerrufsfrist absenden.

Auswirkungen des Widerrufs

Wenn Sie diesen Vertrag widerrufen, erstatten wir Ihnen alle Zahlungen, die wir von Ihnen erhalten haben, einschlie�lich der Lieferkosten (mit Ausnahme der zus�tzlichen Kosten, die entstehen, wenn Sie eine andere Art der Lieferung als die von uns angebotene g�nstigste Standardlieferung gew�hlt haben).

Wir k�nnen einen Abzug von der R�ckerstattung f�r den Wertverlust der gelieferten Waren vornehmen, wenn der Verlust auf eine unn�tige Behandlung durch Sie zur�ckzuf�hren ist.

Wir werden die R�ckerstattung unverz�glich und nicht sp�ter als 14 Tage nach dem Tag vornehmen, an dem wir �ber Ihre Entscheidung, diesen Vertrag zu widerrufen, informiert wurden.

F�r die R�ckerstattung verwenden wir dasselbe Zahlungsmittel, das Sie f�r die urspr�ngliche Transaktion verwendet haben, es sei denn, Sie haben ausdr�cklich etwas anderes vereinbart; in keinem Fall werden Ihnen aufgrund einer solchen R�ckerstattung Geb�hren berechnet.

Wir k�nnen die R�ckzahlung verweigern, bis wir die Waren wieder zur�ckerhalten haben oder Sie den Nachweis erbracht haben, dass Sie die Waren zur�ckgesandt haben, je nachdem, was eher eintritt.

Sie m�ssen die Waren unverz�glich und in jedem Fall sp�testens 14 Tage ab dem Tag, an dem Sie uns �ber den Widerruf dieses Vertrags unterrichten, an Revaluation Books, Hounslow, United Kingdom, zur�cksenden oder �bergeben. Die Frist ist eingehalten, wenn Sie die Ware vor Ablauf der Frist von 14 Tagen zur�cksenden. Sie m�ssen die direkten Kosten der R�cksendung der Waren tragen. Sie haften nur f�r einen etwaigen Wertverlust der Waren, der auf eine Behandlung zur�ckzuf�hren ist, die nicht zur Pr�fung der Art, Eigenschaften und Funktionsweise der Waren erforderlich ist.

Ausnahmen vom Widerrufsrecht

Das Widerrufsrecht gilt nicht f�r:

Die Lieferung von Zeitungen, Zeitschriften oder Magazinen mit Ausnahme von Abonnementvertr�gen; und
Die Lieferung digitaler Inhalte, die nicht auf einem physischen Medium (z. B. auf einer CD oder DVD) geliefert werden, wenn Sie bei Ihrer Bestellung akzeptiert haben, dass wir mit der Lieferung beginnen k�nnen und dass Sie nach Beginn der Lieferung den Vertrag nicht mehr widerrufen k�nnen.

Versandbedingungen

Orders usually dispatched within two working days.

Versandkosten von Vereinigtes K�nigreich nach USA

Versandkosten von Vereinigtes K�nigreich nach USA
Bestellmenge	7 bis 14�Werktage	2 bis 3�Werktage
Erster Artikel	EUR 14.64	EUR 29.28

Die Versandzeiten werden von den Verk�uferinnen und Verk�ufern festgelegt. Sie variieren je nach Versanddienstleister und Standort. Sendungen, die den Zoll passieren, k�nnen Verz�gerungen unterliegen. Eventuell anfallende Abgaben oder Geb�hren sind von der K�uferin bzw. dem K�ufer zu tragen. Die Verk�uferin bzw. der Verk�ufer kann Sie bez�glich zus�tzlicher Versandkosten kontaktieren, um einen m�glichen Anstieg der Versandkosten f�r Ihre Artikel auszugleichen.